Dr. Ai on the Efficacy of Brentuximab Vedotin in Patients With Advanced Cutaneous T-Cell Lymphoma
5 Vues
• 08/09/23
0
0
Intégrer
administrator
Les abonnés
Weiyun Z. Ai, MD, PhD, assistant clinical professor, Department of Medicine, University of California San Francisco, discusses the scenarios in which she has seen the most benefit from brentuximab vedotin (Adcetris) in patients with advanced stage cutaneous T-cell lymphoma (CTCL).
Montre plus
Commentaires de Facebook
SORT BY-
Meilleures Commentaires
-
Derniers Commentaires